La Jolla Pharmaceutical Company Announces Negative Results Of Interim Efficacy Analysis For Riquent Phase 3 ASPEN Trial
Main Category: LupusAlso Included In: Clinical Trials / Drug Trials; Pharma Industry / Biotech Industry
Article Date: 16 Feb 2009 - 4:00 PDT
email to a friend 
printer friendly 
view / write opinions 
rate articleCurrent Article Ratings:
| Patient / Public: |  |
3 (2 votes) |
| Health Professional: |  |
|
| Article Opinions: | 0 posts |
La Jolla Pharmaceutical Company (Nasdaq:LJPC) announced today that the Independent Data Monitoring Board for the Riquent® Phase 3 ASPEN study has informed the Company that they have completed the first interim efficacy analysis and determined that continuing the study is futile. The Company has decided to stop the study, unblind the data and evaluate the results. The Company expects to provide additional guidance on its strategic options going forward in the near future.
La Jolla Pharmaceutical Company
|
Please rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Lupus headlines email to a friend printer friendly version
weekly newsletter daily news alerts
personalize your news
rss feeds
back to top
Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
Please send any medical news or health news press releases to:
| Back to top | Back to front page | List of All Medical Articles |
| Privacy Policy | Terms and Conditions | © 2009 MediLexicon International Ltd |
